These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 24101650)

  • 1. The value of and challenges for cholera vaccines in Africa.
    von Seidlein L; Jiddawi M; Grais RF; Luquero F; Lucas M; Deen J
    J Infect Dis; 2013 Nov; 208 Suppl 1():S8-14. PubMed ID: 24101650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of oral cholera vaccine in a stable refugee population at risk for epidemic cholera and in a population with endemic cholera.
    Murray J; McFarland DA; Waldman RJ
    Bull World Health Organ; 1998; 76(4):343-52. PubMed ID: 9803585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar.
    Schaetti C; Weiss MG; Ali SM; Chaignat CL; Khatib AM; Reyburn R; Duintjer Tebbens RJ; Hutubessy R
    PLoS Negl Trop Dis; 2012; 6(10):e1844. PubMed ID: 23056660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholera in Africa: new momentum in fighting an old problem.
    Mengel MA
    Trans R Soc Trop Med Hyg; 2014 Jul; 108(7):391-2. PubMed ID: 24836060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When, how, and where can oral cholera vaccines be used to interrupt cholera outbreaks?
    Clemens J; Holmgren J
    Curr Top Microbiol Immunol; 2014; 379():231-58. PubMed ID: 24402712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategy, demand, management, and costs of an international cholera vaccine stockpile.
    Maskery B; DeRoeck D; Levin A; Kim YE; Wierzba TF; Clemens JD
    J Infect Dis; 2013 Nov; 208 Suppl 1():S15-22. PubMed ID: 24101640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Social and cultural determinants of anticipated acceptance of an oral cholera vaccine prior to a mass vaccination campaign in Zanzibar.
    Schaetti C; Chaignat CL; Hutubessy R; Khatib AM; Ali SM; Schindler C; Weiss MG
    Hum Vaccin; 2011 Dec; 7(12):1299-308. PubMed ID: 22108036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving immunization approaches to cholera.
    Saha A; Rosewell A; Hayen A; MacIntyre CR; Qadri F
    Expert Rev Vaccines; 2017 Mar; 16(3):235-248. PubMed ID: 27805467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achievements and challenges for the use of killed oral cholera vaccines in the global stockpile era.
    Desai SN; Pezzoli L; Alberti KP; Martin S; Costa A; Perea W; Legros D
    Hum Vaccin Immunother; 2017 Mar; 13(3):579-587. PubMed ID: 27813703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholera vaccine: new preventive tool for endemic countries.
    Verma R; Khanna P; Chawla S
    Hum Vaccin Immunother; 2012 May; 8(5):682-4. PubMed ID: 22634452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The case for reactive mass oral cholera vaccinations.
    Reyburn R; Deen JL; Grais RF; Bhattacharya SK; Sur D; Lopez AL; Jiddawi MS; Clemens JD; von Seidlein L
    PLoS Negl Trop Dis; 2011 Jan; 5(1):e952. PubMed ID: 21283614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When should cholera vaccine be used in cholera-endemic areas?
    Sack DA
    J Health Popul Nutr; 2003 Dec; 21(4):299-303. PubMed ID: 15038584
    [No Abstract]   [Full Text] [Related]  

  • 13. Public health. No vaccines in the time of cholera.
    Enserink M
    Science; 2010 Sep; 329(5998):1462-3. PubMed ID: 20847246
    [No Abstract]   [Full Text] [Related]  

  • 14. Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study.
    Khatib AM; Ali M; von Seidlein L; Kim DR; Hashim R; Reyburn R; Ley B; Thriemer K; Enwere G; Hutubessy R; Aguado MT; Kieny MP; Lopez AL; Wierzba TF; Ali SM; Saleh AA; Mukhopadhyay AK; Clemens J; Jiddawi MS; Deen J
    Lancet Infect Dis; 2012 Nov; 12(11):837-44. PubMed ID: 22954655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and future cholera vaccines.
    Shaikh H; Lynch J; Kim J; Excler JL
    Vaccine; 2020 Feb; 38 Suppl 1():A118-A126. PubMed ID: 31879125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Public health. The cholera crisis in Africa.
    Bhattacharya S; Black R; Bourgeois L; Clemens J; Cravioto A; Deen JL; Dougan G; Glass R; Grais RF; Greco M; Gust I; Holmgren J; Kariuki S; Lambert PH; Liu MA; Longini I; Nair GB; Norrby R; Nossal GJ; Ogra P; Sansonetti P; von Seidlein L; Songane F; Svennerholm AM; Steele D; Walker R
    Science; 2009 May; 324(5929):885. PubMed ID: 19443768
    [No Abstract]   [Full Text] [Related]  

  • 17. The projected impact of geographic targeting of oral cholera vaccination in sub-Saharan Africa: A modeling study.
    Lee EC; Azman AS; Kaminsky J; Moore SM; McKay HS; Lessler J
    PLoS Med; 2019 Dec; 16(12):e1003003. PubMed ID: 31825965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal allocation of the limited oral cholera vaccine supply between endemic and epidemic settings.
    Moore SM; Lessler J
    J R Soc Interface; 2015 Oct; 12(111):20150703. PubMed ID: 26423441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sociocultural determinants of anticipated oral cholera vaccine acceptance in three African settings: a meta-analytic approach.
    Sundaram N; Schaetti C; Merten S; Schindler C; Ali SM; Nyambedha EO; Lapika B; Chaignat CL; Hutubessy R; Weiss MG
    BMC Public Health; 2016 Jan; 16():36. PubMed ID: 26762151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of mass vaccination campaign with oral cholera vaccines in response to an outbreak in Guinea.
    Ciglenecki I; Sakoba K; Luquero FJ; Heile M; Itama C; Mengel M; Grais RF; Verhoustraeten F; Legros D
    PLoS Med; 2013; 10(9):e1001512. PubMed ID: 24058301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.